Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea

Gabriel Tremblay,1 Unnati Majethia,2 Janis L Breeze,3 Ilias Kontoudis,4 Jeongae Park5 1Geneconomics Inc., Lévis, Quebec, Canada; 2Global Value and Access, Eisai Inc., Woodcliff Lake, NJ, 3Tufts Clinical and Translational Science Institute, Tufts University, and Institute for Clinical Rese...

Full description

Bibliographic Details
Main Authors: Tremblay G, Majethia U, Breeze JL, Kontoudis I, Park J
Format: Article
Language:English
Published: Dove Medical Press 2016-09-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
eribulin
metastatic breast cancer
cost-utility
economic analysis
Online Access:https://www.dovepress.com/economic-evaluation-of-eribulin-as-second-line-treatment-for-metastati-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/economic-evaluation-of-eribulin-as-second-line-treatment-for-metastati-peer-reviewed-article-CEOR

Similar Items